Shareholders Reject Chemed's Executive Compensation Plan
Summary
Chemed Corporation's shareholders rejected the executive compensation program at the annual meeting, indicating strong dissent regarding executive pay.
Key Events
-
Executive Compensation Rejected
The non-binding proposal to approve the company's executive compensation program was not approved, with 6,926,656 votes against compared to 4,383,683 votes for.
-
Directors Re-elected
All nine nominated directors, including Kevin J. McNamara and Ron DeLyons, were re-elected to the Board of Directors.
-
Independent Accountants Ratified
Shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent accountants for the year ending December 31, 2026.
Analysis
Shareholders voted against the company's executive compensation program in a non-binding 'Say-on-Pay' vote. This outcome signals significant shareholder dissatisfaction with current compensation practices and will likely pressure the Board of Directors and Compensation Committee to review and potentially revise executive pay structures.
At the time of this filing, CHE was trading at $443.20 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.9B. The 52-week trading range was $365.21 to $583.96. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.